These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37865978)

  • 41. [Hereditary haematological malignancies].
    Kotmayer L; Kállay K; Bödör C
    Magy Onkol; 2020 Mar; 64(1):43-55. PubMed ID: 32181762
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identifying patients with genetic predisposition to acute myeloid leukemia.
    Obrochta E; Godley LA
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):373-378. PubMed ID: 30466750
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition.
    Kanagal-Shamanna R
    Curr Hematol Malig Rep; 2021 Aug; 16(4):336-344. PubMed ID: 34028637
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Germline Predisposition to Myeloid Neoplasms: Diagnostic Concepts and Classifications.
    Obiorah IE; Upadhyaya KD; Calvo KR
    Clin Lab Med; 2023 Dec; 43(4):615-638. PubMed ID: 37865507
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes.
    Wong JC; Bryant V; Lamprecht T; Ma J; Walsh M; Schwartz J; Del Pilar Alzamora M; Mullighan CG; Loh ML; Ribeiro R; Downing JR; Carroll WL; Davis J; Gold S; Rogers PC; Israels S; Yanofsky R; Shannon K; Klco JM
    JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046003
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Germline Predisposition in Hematologic Malignancies: Testing, Management, and Implications.
    Godley LA; DiNardo CD; Bolton K
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432218. PubMed ID: 38768412
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple Primary Cancers With Hematologic Malignancies and Germline Predisposition: A Case Series.
    Yun J; Lee DS; Lee S; Yun H
    Ann Lab Med; 2024 Sep; 44(5):446-449. PubMed ID: 38449380
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Section E6.1-6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow-acquired chromosomal abnormalities.
    Mikhail FM; Heerema NA; Rao KW; Burnside RD; Cherry AM; Cooley LD
    Genet Med; 2016 Jun; 18(6):635-42. PubMed ID: 27124785
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytogenetic analysis in patients with primary myelodysplastic syndromes in leukaemic transformation. A report on 94 cases. Groupe Français de Cytogénétique Hématologique (GFCH).
    Hematol Cell Ther; 1996 Apr; 38(2):177-81. PubMed ID: 8931999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes.
    Sahoo SS; Kozyra EJ; Wlodarski MW
    Best Pract Res Clin Haematol; 2020 Sep; 33(3):101197. PubMed ID: 33038986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Practical considerations for diagnosis and management of patients and carriers.
    Niemeyer CM; Mecucci C
    Semin Hematol; 2017 Apr; 54(2):69-74. PubMed ID: 28637619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Location and function of critical genes in leukemogenesis inferred from cytogenetic abnormalities in hematologic malignancies.
    Bernard OA; Berger R
    Semin Hematol; 2000 Oct; 37(4):412-9. PubMed ID: 11071362
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Guiding the global evolution of cytogenetic testing for hematologic malignancies.
    Akkari YMN; Baughn LB; Dubuc AM; Smith AC; Mallo M; Dal Cin P; Diez Campelo M; Gallego MS; Granada Font I; Haase DT; Schlegelberger B; Slavutsky I; Mecucci C; Levine RL; Hasserjian RP; Solé F; Levy B; Xu X
    Blood; 2022 Apr; 139(15):2273-2284. PubMed ID: 35167654
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique.
    Leroux D; Mugneret F; Callanan M; Radford-Weiss I; Dastugue N; Feuillard J; Le Mée F; Plessis G; Talmant P; Gachard N; Uettwiller F; Pages MP; Mozziconacci MJ; Eclache V; Sibille C; Avet-Loiseau H; Lafage-Pochitaloff M
    Blood; 2002 Jun; 99(11):4154-9. PubMed ID: 12010820
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Français de Cytogénétique Hématologique.
    Blood; 1996 Apr; 87(8):3135-42. PubMed ID: 8605327
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology.
    Ripperger T; Bielack SS; Borkhardt A; Brecht IB; Burkhardt B; Calaminus G; Debatin KM; Deubzer H; Dirksen U; Eckert C; Eggert A; Erlacher M; Fleischhack G; Frühwald MC; Gnekow A; Goehring G; Graf N; Hanenberg H; Hauer J; Hero B; Hettmer S; von Hoff K; Horstmann M; Hoyer J; Illig T; Kaatsch P; Kappler R; Kerl K; Klingebiel T; Kontny U; Kordes U; Körholz D; Koscielniak E; Kramm CM; Kuhlen M; Kulozik AE; Lamottke B; Leuschner I; Lohmann DR; Meinhardt A; Metzler M; Meyer LH; Moser O; Nathrath M; Niemeyer CM; Nustede R; Pajtler KW; Paret C; Rasche M; Reinhardt D; Rieß O; Russo A; Rutkowski S; Schlegelberger B; Schneider D; Schneppenheim R; Schrappe M; Schroeder C; von Schweinitz D; Simon T; Sparber-Sauer M; Spix C; Stanulla M; Steinemann D; Strahm B; Temming P; Thomay K; von Bueren AO; Vorwerk P; Witt O; Wlodarski M; Wössmann W; Zenker M; Zimmermann S; Pfister SM; Kratz CP
    Am J Med Genet A; 2017 Apr; 173(4):1017-1037. PubMed ID: 28168833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytogenetic study of 75 erythroleukemias.
    Lessard M; Struski S; Leymarie V; Flandrin G; Lafage-Pochitaloff M; Mozziconacci MJ; Talmant P; Bastard C; Charrin C; Baranger L; Hélias C; Cornillet-Lefebvre P; Mugneret F; Cabrol C; Pagès MP; Fert-Ferret D; Nguyen-Khac F; Quilichini B; Barin C; Berger R;
    Cancer Genet Cytogenet; 2005 Dec; 163(2):113-22. PubMed ID: 16337853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope.
    Elghetany MT; Patnaik MM; Khoury JD
    Leuk Res; 2024 Feb; 137():107441. PubMed ID: 38301422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. t(5;14)/HOX11L2-positive T-cell acute lymphoblastic leukemia. A collaborative study of the Groupe Français de Cytogénétique Hématologique (GFCH).
    Berger R; Dastugue N; Busson M; Van Den Akker J; Pérot C; Ballerini P; Hagemeijer A; Michaux L; Charrin C; Pages MP; Mugneret F; Andrieux J; Talmant P; Hélias C; Mauvieux L; Lafage-Pochitaloff M; Mozziconacci MJ; Cornillet-Lefebvre P; Radford I; Asnafi V; Bilhou-Nabera C; Nguyen Khac F; Léonard C; Speleman F; Poppe B; Bastard C; Taviaux S; Quilichini B; Herens C; Grégoire MJ; Cavé H; Bernard OA;
    Leukemia; 2003 Sep; 17(9):1851-7. PubMed ID: 12970786
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [How to capture cytogenetic and molecular abnormalities into ProMISe database for hematological malignancies: Guidelines from the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].
    Raus N; Karam M; Chebel R; Dantin C; Pereira M; Wallart A; Yakoub-Agha I; Srour M
    Bull Cancer; 2020 Jan; 107(1S):S52-S61. PubMed ID: 31615645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.